


Curriculum Vitae



PERSONAL INFORMATION

First Name: Ghasem **Last Name: Solgi**

Birth Day: 21-Mar-1976

Nationality: Iranian

Contact Information: email: gh.solgi@umsha.ac.ir and ghsolgi2@yahoo.com

Tel: +98 (81) 38247143, Cell phone: +98 (912) 5113220

EDUCATION

- **2008-2009:** Practical course, Transplantation Immunology, IKT, Ulm, Germany
 - **2004-2009:** Ph.D. in Medical Immunology, Tehran University of Medical Sciences, Tehran, Iran.
Thesis: Effect of donor bone marrow cells infusion on microchimerism and allograft outcomes in kidney transplant patients, A Five-Year follow-up study
 - **200-2002:** M.Sc. in Medical Immunology, Isfahan University of Medical Sciences, Isfahan, Iran
Thesis: Comparison of serological and DNA-based methods for HLA typing in kidney allograft recipients.
-

WORK EXPERIENCE

- **September 2020 –present:** Head of Immunogenetics Lab, Immunology Department, Hamadan University of Medical Sciences, Hamadan, Iran.
- **September 2016-2020:** Deputy for Research Affairs for Medical School, Hamadan University of Medical Sciences, Hamadan, Iran.
- **October 2015-Dec 2019:** Head of Immunology Department, Hamadan University of Medical Sciences.
- **September 2012- Oct 2015:** Assistant professor in Immunology Department, Hamadan University of Medical Sciences, Hamadan, Iran.
- **December 2009- Sept 2012:** Assistant professor in Immunology Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

RESEARCH EXPERIENCES

- Early evaluation of anti HLA antibody screening in relation to kidney allograft outcomes.
- Analysis of allelic distributions of HLA class II alleles in T1D patients.
- Alleleic and haplotypic analysis of HLA genes in terms of disease susceptibility/protection and therapeutic responses to biological treatment in MS patients

- The link between HLA shared epitope alleles and pattern of response to therapy in RA patients
- Relevance of HLA class II alleles and haplotypes with autoantibody profiles and clinical presentations in SLE patients.
- Disease severity and susceptibility in relation to HLA class I and class II alleles distributions in COVID-19 patients
- Survival analysis of kidney transplant patients.

PUBLICATIONS

1. Tahamoli-Roudsari A, Tabatabaei R, Alvandpur N, Basiri Z, Behzad M, Rezaeepoor M, Abdolmaleki M, Fouladseresht H, Roshanaei G, Hajilooi M, **Solgi G**. Peripheral distributions of IL-4-producing CD4 + T cells and CD4 + CD25 + FoxP3 + T cells (Tregs) in rheumatoid arthritis patients with poor response to therapy are associated with HLA shared epitope alleles and ACPA status. **Immunol Res.** **2022** Aug;70(4):481-492. doi: 10.1007/s12026-022-09281-0. Epub 2022 Apr 21. PMID: 35445929.
2. Basir HRG, Majzoobi MM, Ebrahimi S, Noroozbeygi M, Hashemi SH, Keramat F, Mamani M, Eini P, Alizadeh S, **Solgi G**, Di D. Susceptibility and Severity of COVID-19 Are Both Associated With Lower Overall Viral-Peptide Binding Repertoire of HLA Class I Molecules, Especially in Younger People. **Front Immunol.** **2022** Jul 7;13:891816. doi: 10.3389/fimmu.2022.891816. PMID: 35911710; PMCID: PMC9331187.
3. Ebrahimi S, Ghasemi-Basir HR, Majzoobi MM, Rasouli-Saravani A, Hajilooi M, **Solgi G**. HLA-DRB1*04 may predict the severity of disease in a group of Iranian COVID-19 patients. **Hum Immunol.** **2021** Oct;82(10):719-725. doi: 10.1016/j.humimm.2021.07.004. Epub 2021 Jul 13. PMID: 34294460; PMCID: PMC8275473.
4. Rasouli-Saravani A, Tahamoli-Roudsari A, Basiri Z, Babaei M, Fazaeli A, Roshanaei G, Hajilooi M, **Solgi G**. Relevance of autoantibody profile with HLA- DRB1 and -DQB1 alleles

- in a group of Iranian systemic lupus erythematosus patients. **Immunol Lett.** **2021** Sep;237:11-16. doi: 10.1016/j.imlet.2021.06.004. Epub 2021 Jun 26. PMID: 34186156.
5. Rezalotfi A, **Solgi G**, Ebrahimi M. Gastrospheres as a Model of Gastric Cancer Stem Cells Skew Th17/Treg Balance toward Antitumor Th17 Cells. **J Immunol Res.** **2020** Dec 23;2020:6261814. doi: 10.1155/2020/6261814. PMID: 33426090; PMCID: PMC7775146.
 6. Gheitasi R, Keramat F, **Solgi G**, Hajilooi M. Investigation of Linc-MAF-4 expression as an effective marker in brucellosis. **Mol Immunol.** **2020** Jul;123:60-63. doi: 10.1016/j.molimm.2020.04.022. Epub 2020 May 14. PMID: 32417631.
 7. Rezaeepoor M, Pourjafar M, Tahamoli-Roudsari A, Basiri Z, Hajilooi M, Solgi G. Altered expression of microRNAs may predict therapeutic response in rheumatoid arthritis patients. **Int Immunopharmacol.** **2020** Jun;83:106404. doi: 10.1016/j.intimp.2020.106404. Epub 2020 Mar 18. PMID: 32197230.
 8. Alvandpur N, Tabatabaei R, Tahamoli-Roudsari A, Basiri Z, Behzad M, Rezaeepoor M, Roshanaei G, Hajilooi M, Solgi G. Circulating IFN- γ producing CD4+ T cells and IL-17A producing CD4+ T cells, HLA-shared epitope and ACPA may characterize the clinical response to therapy in rheumatoid arthritis patients. **Hum Immunol.** **2020** May;81(5):228-236. doi: 10.1016/j.humimm.2020.02.008. Epub 2020 Feb 24. PMID: 32107036.
 9. Ahamadi-Fesharaki R, Fateh A, Vaziri F, Solgi G, Siadat SD, Mahboudi F, Rahimi-Jamnani F. Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow. **Mol Ther Oncolytics.** **2019** Mar 23;14:38-56. doi: 10.1016/j.omto.2019.02.004. PMID: 31011631; PMCID: PMC6463744.
 10. Rezalotfi A, Ahmadian E, Aazami H, Solgi G, Ebrahimi M. Gastric Cancer Stem Cells Effect on Th17/Treg Balance; A Bench to Beside Perspective. **Front Oncol.** **2019** Apr 5;9:226. doi: 10.3389/fonc.2019.00226. PMID: 31024835; PMCID: PMC6464032.

11. Hosseinzadeh M, Ahmadpoor P, Yekaninejad MS, Pourrezaghali F, Foroughi F, Ghorbanpour M, Barabadi M, Shahbaz SK, **Solgi G**, Amirzargar A. Expression patterns of Toll like receptor (TLR)-2, TLR-4 and myeloid differentiation primary response gene 88 (MYD88) in renal transplant patients developing allograft dysfunction; a cohort study. **Transpl Immunol.** **2018** Jun;48:26-31. doi: 10.1016/j.trim.2018.02.005. Epub 2018 Feb 13. PMID: 29452169.
12. Mazdeh M, Moradi N, Khoshroo E, Shayesteh Z, Taheri M, Sayad A, Omrani MD, Hajilooi M, Roshanaei G, Solgi G. Down-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta. **J Neuroimmunol.** **2018** Jan 15;314:24-29. doi: 10.1016/j.jneuroim.2017.11.004. Epub 2017 Nov 8. PMID: 29157944.
13. Mohammadi F, **Solgi G**, Tajik M, Ahmadpoor P, Nikoeinejad H, Einollahi B, Nazari B, Lessan-Pezeshki M, Amirzargar A. Enzyme-Linked Immunosorbent Spot (ELISpot) monitoring of cytokine-producing cells for the prediction of acute rejection in renal transplant patients. **Eur Cytokine Netw.** **2017** Sep 1;28(3):93-101. doi: 10.1684/ecn.2017.0397. PMID: 29187340.
14. Amirzargar MA, Yaghubi F, Hosseinpanah M, Jafari M, Pourjafar M, Rezaeepoor M, Rezaei H, Roshanaei G, Hajilooi M, **Solgi G**. Anti-inflammatory Effects of Valproic Acid in a Rat Model of Renal Ischemia/Reperfusion Injury: Alteration in Cytokine Profile. **Inflammation.** **2017** Aug;40(4):1310-1318. doi: 10.1007/s10753-017-0574-9. PMID: 28478517.
15. Marzban A, Kiani J, Hajilooi M, Rezaei H, Kahramfar Z, Solgi G. HLA class II alleles and risk for peripheral neuropathy in type 2 diabetes patients. **Neural Regen Res.** **2016** Nov;11(11):1839-1844. doi: 10.4103/1673-5374.194756. PMID: 28123430; PMCID: PMC5204242.
16. Mazdeh M, Taheri M, Sayad A, Bahram S, Omrani MD, Movafagh A, Inoko H, Akbari MT, Noroozi R, Hajilooi M, Solgi G. HLA genes as modifiers of response to IFN- β -1a therapy in

relapsing-remitting multiple sclerosis. **Pharmacogenomics**. 2016 Apr;17(5):489-98. doi: 10.2217/pgs.16.2. Epub 2016 Mar 29. PMID: 27020477.

17. Kiani J, Hajilooi M, Furst D, Rezaei H, Shahryari-Hesami S, Kowsarifard S, Zamani A, **Solgi G**. HLA class II susceptibility pattern for type 1 diabetes (T1D) in an Iranian population. **Int J Immunogenet**. 2015 Aug;42(4):279-86. doi: 10.1111/iji.12216. Epub 2015 Jun 18. PMID: 26088816.
18. Amirzargar MA, Amirzargar A, Basiri A, Hajilooi M, Roshanaei G, Rajabi G, Mohammadiazar S, **Solgi G**. Early post-transplant immune monitoring can predict long-term kidney graft survival: soluble CD30 levels, anti-HLA antibodies and IgA-anti-Fab autoantibodies. **Hum Immunol**. 2014 Jan;75(1):47-58. doi: 10.1016/j.humimm.2013.09.010. Epub 2013 Sep 17. PMID: 24055694.
19. **Solgi G**, Gadi V, Paul B, Mytilineos J, Pourmand G, Mehrsai A, Ranjbar M, Mohammadnia M, Nikbin B, Amirzargar AA. Five-year clinical effects of donor bone marrow cells infusions in kidney allograft recipients: improved graft function and higher graft survival. **Chimerism**. 2013 Jul-Sep;4(3):87-94. doi: 10.4161/chim.24719. Epub 2013 May 31. PMID: 23639966; PMCID: PMC3782550.
20. Ranjbar M, **Solgi G**, Mohammadnia M, Nikbin B, Pourmand G, Ansari-pour B, Amirzargar A. Regulatory T-cell subset analysis and profile of interleukin (IL)-10, IL-17 and interferon-gamma cytokine-producing cells in kidney allograft recipients with donor cells infusion. **Clin Exp Nephrol**. 2012 Aug;16(4):636-46. doi: 10.1007/s10157-012-0591-9. PMID: 22314659.
21. **Solgi G**, Furst D, Mytilineos J, Pourmand G, Amirzargar AA. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. **Transpl Immunol**. 2012 Mar;26(2-3):81-7. doi: 10.1016/j.trim.2011.12.002. Epub 2011 Dec 13. PMID: 22182633.

22. **Solgi G**, Ghafari H, Ashouri E, Alimoghdam K, Rajalingam R, Amirzargar A. Comparison of KIR gene content profiles revealed a difference between northern and southern Persians in the distribution of KIR2DS5 and its linked loci. **Hum Immunol.** **2011** Nov;72(11):1079-83. doi: 10.1016/j.humimm.2011.08.002. Epub 2011 Aug 10. PMID: 21867738.
23. **Solgi G**, Mytilineos J, Gadi V, Paul B, Pourmand G, Mehraei A, Nikbin B, Amirzargar AA. Donor-derived peripheral mononuclear cell DNA is associated with stable kidney allograft function: a randomized controlled trial. **Chimerism.** **2011** Oct-Dec;2(4):102-10. doi: 10.4161/chim.2.4.19095. PMID: 22509426; PMCID: PMC3321880.
24. Lotfi R, Eisenbacher J, **Solgi G**, Fuchs K, Yildiz T, Nienhaus C, Rojewski MT, Schrezenmeier H. Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material. **Eur J Immunol.** **2011** Jul;41(7):2021-8. doi: 10.1002/eji.201041324. PMID: 21538978.
25. Fürst D, **Solgi G**, Recker K, Mytilineos D, Schrezenmeier H, Mytilineos J. Sequence-based typing of major histocompatibility complex class I chain-related gene A alleles by use of exons 2-5 information. **Tissue Antigens.** **2011** Mar;77(3):201-5. doi: 10.1111/j.1399-0039.2010.01601.x. PMID: 21299524.
26. Fürst D, **Solgi G**, Schrezenmeier H, Mytilineos J. The frequency of DRB1*1454 in South German Caucasians. **Tissue Antigens.** **2010** Jul;76(1):57-9. doi: 10.1111/j.1399-0039.2010.01461.x. Epub 2010 Mar 4. PMID: 20210922.

Link for more publications: <https://pubmed.ncbi.nlm.nih.gov/?term=solgi+g&sort=pubdate>

PRESENTATIONS

ORAL AND POSTER

Title: Susceptibility and severity of COVID-19 both associated with lower overall viral peptide binding repertoire of HLA class I but not class II molecules, especially in younger people

Author(s): Di, D; Solgi, G

Source: HLA Meeting Abstract: P182 **Volume:** 99 **Issue:** 5 **Special Issue:** SI **Pages:** 533-533 **Published:** MAY 2022

Accession Number: WOS:000788004300256

Title: Contribution of HLA-A, -B, -C and-DRB1 alleles and haplotypes to susceptibility and severity of COVID-19 in a group of Iranians

Author(s): Ghasemi-Basir, HR; Majzoobi, MM; Ebrahimi, S; Noroozbeygi, M; Hashemi, SH ; Keramat, F; Mamani, M; Eini, P; Solgi, G; Di, D.

Source: HLA Meeting Abstract: P165 **Volume:** 99 **Issue:** 5 **Special Issue:** SI **Pages:** 525-525 **Published:** MAY 2022

Accession Number: WOS:000788004300239

Title: CLOSE LINK WITH HLA SHARED EPITOPE ALLELES AND ACPA STATUS AND PERIPHERAL DISTRIBUTION OF CD4+CD25+FOXP3+T CELLS (TREG) IN RHEUMATOID ARTHRITIS PATIENTS

Author(s): Solgi, G., Tahamoli-Roudsari, A., Tabatabaei, R., Alvandpur, N; Basiri, Z., Behzad, M., Hajilooi, M

Source: HLA Meeting Abstract: O77 **Volume:** 97 **Issue:** 4 **Pages:** 307-307 **Published:** APR 2021

Accession Number: WOS:000628818700029

Title: HLA-DRB1*04 ALLELE GROUP AND DISEASE SEVERITY IN COVID-19 PATIENTS

Author(s): Solgi, G ; Ebrahimi, S; Reza, HRH; Majzoobi, MM; Rasouli-Saravani, A; Hajilooi, M

Source: HLA Meeting Abstract: O87 **Volume:** 97 **Issue:** 4 **Pages:** 312-313 **Published:** APR 2021

Accession Number: WOS:000628818700039

Title: Gastro-sphere effects on Th17/Treg diagram: Help or hindrance?

Author(s): Rezalotfi, A; Solgi, G ; Ebrahimi, M

Source: ANNALS OF ONCOLOGY **Meeting Abstract:** 90P **Volume:** 31 **Pages:** S1453-S1453 **DOI:** 10.1016/j.annonc.2020.10.578 **Supplement:** 7 **Published:** DEC 2020

Accession Number: WOS:000600992500090

Conference Title: ESMO Immuno-Oncology Virtual Congress

Conference Date: DEC 09-12, 2020

Title: DECAY IN LINKAGE DISEQUILIBRIUM OF HLA HAPLOTYPE-DEFINING SNPS IN IRANIAN TYPE 1 DIABETES SUBJECTS

Author(s): Solgi, G ; Rezaei, H; Samadi, M; Jamehbozorg, S ; Taheri, M; Hajilooi, M; Kiani; Morahan, G.

Source: HLA **Meeting Abstract:** P71 **Volume:** 93 **Issue:** 5 **Special Issue:** SI **Pages:** 323-324 **Published:** MAY 2019

Accession Number: WOS:000464517600147

Title: Gastric cancer stem-like cells, the balance operator of Th17 and Treg

Author(s): Rezalotfi, A; Ebrahimi, M, Solgi, G.

Source: ANNALS OF ONCOLOGY **Meeting**

Abstract: 92P **Volume:** 28 **Supplement:** 11 **Published:** DEC 2017

Accession Number: WOS:000424778900082

Conference Title: ESMO Immuno Oncology Congress

Conference Date: DEC 07-10, 2017

Title: FIVE-YEAR CLINICAL EFFECTS OF DONOR BONE MARROW CELLS INFUSIONS IN KIDNEY ALLOGRAFT RECIPIENTS

Author(s): Solgi, G; Gadi, V; Pourmand, G; Mehraei, A; Ranjbar, M; Mohammadnia, M; Nikbin, B; Amirzargar, AA

Source: JOURNAL OF UROLOGY **Meeting Abstract:** MP41-03 **Volume:** 197 **Issue:** 4 **Pages:** E532-E532 **DOI:** 10.1016/j.juro.2017.02.1271 **Supplement:** S **Published:** APR 2017

Accession Number: WOS:000398276602151

Conference Title: Annual Meeting of the American-Urological-Association (AUA)

Title: HLA ALLELES MAY PREDICT RESPONSE TO IFN-B-1A THERAPY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

Author(s): Solgi, G; Taheri, M; Sayad, A; Omrani, MD; Movafagh, A; Mazdeh, M; Akbari, MT; Norouzi, R; Hajilooi, M

Source: HLA Meeting Abstract: P191 **Volume:** 87 **Issue:** 4 **Pages:** 310-310 **Published:** APR 2016

Accession Number: WOS:000383951500273

Title: CORRELATION BETWEEN HLA CLASS II ALLELES AND PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES PATIENTS IN IRAN

Author(s): Solgi, G; Kiani, J; Kahramfar, Z ; Marzban, A; Rezaei, H ; Hajilooi, M

Source: TISSUE ANTIGENS **Meeting Abstract:** P02 **Volume:** 85 **Issue:** 5 **Pages:** 330-330 **Published:** MAY 2015

Accession Number: WOS:000352907000079

Conference Title: European-Federation-for-Immunogenetics Conference

Conference Date: APR 26-29, 2015

Title: ASSOCIATION BETWEEN HLA-DRB1/DQB1 ALLELES AND HAPLOTYPES AND PEMPHIGUS VULGARIS IN HAMADAN, WEST-IRAN

Author(s): Solgi, G ; Motemayel, FA; Rezaei, H; Mandian, M ; Hajilooi, M

Source: TISSUE ANTIGENS **Meeting Abstract:** P19 **Volume:** 85 **Issue:** 5 **Pages:** 336-337 **Published:** MAY 2015

Accession Number: WOS:000352907000096

Conference Title: European-Federation-for-Immunogenetics Conference

Conference Date: APR 26-29, 2015

Title: ASSOCIATION OF HLA-DRB1 AND DQB1 ALLELES AND HAPLOTYPES WITH TYPE ONE DIABETES IN HAMADAN, WEST-IRAN

Author(s): Solgi, G; Kiani, J ; Fuerst, D; Shahryari, SH ; Rezaei, H; Kosari, S; Zamani, A; Hajilooi, M

Source: TISSUE ANTIGENS **Volume:** 84 **Issue:** 1 **Pages:** 138-139 **Published:** JUL 2014

Accession Number: WOS:000337546000335

Conference Title: 28th EFI European Immunogenetics and Histocompatibility Conference

Conference Date: JUN 25-28, 2014

Title: THREE YEARS FOLLOW-UP OF KIDNEY ALLOGRAFT RECIPIENTS WITH CONCURRENT DONOR CELLS INFUSION

Author(s): Solgi, G; Mytilneos, J; Gadi, V; Paul, B; Pourmand, G; Ranjbar, M ; Nikbin, B; Amirzargar, A

Source: TISSUE ANTIGENS **Volume:** 79 **Issue:** 6 **Pages:** 417-418 **Published:** JUN 2012

Accession Number: WOS:000303499800037

Conference Title: Joint 16th International HLA and Immunogenetics Workshop/26th European Federation for Immunogenetics Conference/23rd British-Society-of-Histocompatibility-and-Immunogenetics Conference

Conference Date: MAY 31-JUN 03, 2012

Link for more conference papers: <https://www2.wosgs.ir/wos/woscc/summary/07a9ced8-ee6c-4260-937a-ea9628d3d5ce-4cb51134/relevance/1>

EDITORIAL EXPERIENCE

- Reviewed manuscripts for:
 - Diagnostics
 - Current Diabetes review
 - Human Immunology
 - Journal of Neurological Sciences
 - Antiviral therapy
 - Immunobiology
 - Journal of Clinical Medicine
 - Molecular Biology Reports
 - Scientific reports
 - Gene Reports
 - Iranian Journal of Immunology
 - Iranian Journal of Allergy, Asthma, and Immunology
 - Viral Immunology
 - Journal of Medical Virology
 - Immunological Investigations
 -
-

Selected SUPERVISORY EXPERIENCE

- **2022: Marzieh Abbasi, PhD Student**, Hamadan University of Medical Sciences, Hamdan, Iran.
- **2021 Samaneh Ebrahimi, MSc Student**, Hamadan University of Medical Sciences,
- **2020 Ashkan Rasuli-Saravani, MSc Student**, Hamadan University of Medical Sciences,

- **2020 Reza Gheitasi, MSc Student, Hamadan University of Medical Sciences,**
 - **2019 Alaleh Rezalotfi, MSc Student, Hamadan University of Medical Sciences,**
 - **2018 Faramarz Yaqubi, Urology Resident, Hamadan University of Medical Sciences.**
 - **2017 Yazan Heshmati. Neurology Resident, Hamadan University of Medical Sciences,**
 - **2016 Adel Mohamad Alipur, PhD student, Hamadan University of Medical Sciences.**
 - **2015 Elnaz Khoshru, MSc Student, Hamadan University of Medical Sciences,**
 - **2014 Zeynab Bayat, Dentistry Resident, Hamadan University of Medical Sciences,**
 -
-

References

Prof. Joannis Mytilineos,

Chief Medical Officer

ZKRD Central Bone Marrow

Donor Register for the Federal Republic of

Germany

PO Box 4244

89032 Ulm

Tel: +49 731 1507502

Email: joannis.mytilineos@zkrd.de

PD dr medical Daniel Furst

Head of Transplantation Immunology

Institute for Clinical Transfusion Medicine
and Immunogenetics Ulm (IKT)

Helmholtzstraße 10

89081 Ulm

Tel.: +49 731 150-524, Fax: +49 731 150-665

Email: d.fuerst@blutspende.de and
daniel.fuerst@uni-ulm.de